Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2, PHASE3
Sponsor: National Cancer Institute (NCI)
Condition: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
NCT07572123
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | few_sites_large_trial_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.